Cybin, Inc. (TSE:CYBN) has released an update.
Cybin Inc., a clinical-stage biopharmaceutical company, is making significant strides in mental health treatment with its psychedelic-based therapies. The company has secured a substantial $150 million in funding and achieved FDA Breakthrough Therapy Designation for its leading drug CYB003, aimed at treating Major Depressive Disorder. Anticipation is high as Cybin prepares to launch a Phase 3 study for CYB003 in mid-2024 and release Phase 2 results for another treatment, CYB004 for Generalized Anxiety Disorder, in late 2024.
For further insights into TSE:CYBN stock, check out TipRanks’ Stock Analysis page.
